Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/2006
12/06/2006CN1872338A Chewing tablet for discharging lead, and preparation method
12/06/2006CN1872315A Application of medication of containing spatholobus stem in resistant medication anti aspirin
12/06/2006CN1872298A Preparation of Chinese traditional medicine for soothing the nerves and enriching brain of babe, and preparation
12/06/2006CN1872222A Medication of medicinal broth for treating women's convulsion when menstrual onset, and preparation method
12/06/2006CN1872182A Medication for treating thalassemia and preparation method
12/06/2006CN1872177A Application of medication of containing red sage root in resistant medication anti aspirin
12/06/2006CN1872173A Application of composition of containing root-bark of peony in resistant medication anti aspirin
12/06/2006CN1872136A Medication for treating neonatal jaundice, and method of use.
12/06/2006CN1872107A Chinese and Western compound preparations of alpha receptor blocking pharmacon, preparation method, and application
12/06/2006CN1872095A Drop pills of enhancing body immunity and fighting against senium
12/06/2006CN1872071A Medication for enhancing body immunity, and fighting against senium, and preparation method
12/06/2006CN1872041A Medicine use of 3 ú¿3 nitryl 4 hydroxyú®- ethyl acrylate controlled xanthine oxidase
12/06/2006CN1871949A Beverage tea of 'Shoubai'
12/06/2006CN1288238C Koji molds and use thereof for preparing cholesterol-lowering products
12/06/2006CN1288165C A preparation derived from shark cartilage for treatment of diseases related to excessive PHF or excessive intracellular calcium
12/06/2006CN1288153C Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible NO-synthase
12/06/2006CN1288150C Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein junkinases
12/06/2006CN1288148C 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin II receptor antagonists
12/06/2006CN1288143C Azulene derivatives and salts thereof
12/06/2006CN1288137C 7-heterocyclyl quinoline and thieno[2,3,-b] pyridine derivatives useful as antagonists of gonadotropin releasing hormone
12/06/2006CN1287859C Magnetic targeted carrier composed of iron and porous materials for targeted delivery of biologically active agents
12/06/2006CN1287805C Formula of anti-senility tablet and preparing method
12/06/2006CN1287783C Application of probuco monoester in treating angiocardiopathy and inflammatory disease
12/06/2006CN1287781C Use of KCNQ potassium excitant in preparation of medicine with the functions of inducing or maintaining bladder performances
12/06/2006CN1287779C Agents for relieving carbonyl stress
12/06/2006CN1287778C Use of N,N-diethyl-2-[-4-(phenylmethyl)-phenoxy]ethanamine monohydrochloride (dppe) in cancer therapy
12/06/2006CN1287768C Stabilized oral suspension formulation
12/06/2006CN1287766C Product containing an extract of red algae of the genus porphyra and methods for protecting cells
12/06/2006CN1287680C Oral immunostimulation of mammals, birds, fish and reptiles from 1-4 linked ss-d-mannuronic acid
12/06/2006CN1287676C Pestle cereal and its preparing method
12/05/2006USRE39419 Estrogen agonist/antagonist metabolites
12/05/2006US7145032 Treating neuronal injury and for life-extension
12/05/2006US7145009 Pirazino(aza)indole derivatives
12/05/2006US7144997 Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
12/05/2006US7144918 Enzyme inhibitors; anticancer agents
12/05/2006US7144913 Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists
12/05/2006US7144909 Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands
12/05/2006US7144902 Prodrugs of thrombin inhibitors
12/05/2006US7144900 Pharmaceutical composition
12/05/2006US7144897 Substituted amide compound containing hydroxy and amino groups; useful for treating Alzheimer's disease and other similar diseases
12/05/2006US7144893 4-aryl quinols and analogs thereof as therapeutic agents
12/05/2006US7144892 Treatment of cardiovascular and related pathologies
12/05/2006US7144886 Dipeptidyl peptidase IV (DP-IV) inhibitors as anti-diabetic agents
12/05/2006US7144884 E.g., 4-[2-(4-Methylphenoxy)- or 4-[2-(4-Methylphenylsulfanyl)-phenyl]-3,6-dihydro-2H-pyridine or piperazine or the hydrochloride or oxalate; treating depression, anxiety disorder, and obsessive compulsive disorder.
12/05/2006US7144883 Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders
12/05/2006US7144882 Central nervous system disorders; psychological disorders; inflammatory bowel disorders
12/05/2006US7144873 Therapy for anticancer agents, blood disorders; dissolving in nonaqueous solvent
12/05/2006US7144872 1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-carboxamides; adenosine receptors (A2A); for stimulating mammalian coronary vasodilatation for therapy and imaging the heart
12/05/2006US7144870 Gene therapy; lyases; hyaluronidase; anticancer agents (retinoblastomas); kits
12/05/2006US7144707 Determination of risk and treatment of complications of prematurity
12/05/2006US7144589 High functional water containing titanium and method and apparatus for producing the same
12/05/2006US7144586 Compositions for preventing hormone induced adverse effects
12/05/2006US7144569 Mutant gliadin protein whose wild-type sequence can be modified by transglutaminase; fusion protein comprising a non-gliadin sequence; kit comprising antibody to interferon- gamma detects recognition by T-cell
12/05/2006CA2531834C Pharmaceutical compositions comprising pioglitazone and an insulin secretion enhancer
12/05/2006CA2434386C Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
12/05/2006CA2414936C Thiophene retinoids
12/05/2006CA2396458C Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
12/05/2006CA2326630C Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof
12/05/2006CA2293713C Bispyrido-cycloheptane compounds useful for inhibition of farnesyl protein transferase
12/05/2006CA2150382C Process for the preparation of 9-amino camptothecin
12/05/2006CA2146429C 25-carboxylic acid derivatives in the vitamin d series, method of producing them, intermediate products for this method, pharmaceutical preparations containing these derivatives and their use in the manufacture of medicines
11/2006
11/30/2006WO2006127930A2 Nk-b inhibitors for the treatment of muscular dystrophy
11/30/2006WO2006126718A1 Pyrazolopyrimidine derivative
11/30/2006WO2006126714A1 Activator for peroxisome proliferator-activated receptor
11/30/2006WO2006126712A1 Smooth muscle contraction inhibitor
11/30/2006WO2006126695A1 Pyrazole compound and therapeutic agent for diabetes comprising the same
11/30/2006WO2006126675A1 Agent for external application to the skin
11/30/2006WO2006126673A1 Combined drug for treating diabetes
11/30/2006WO2006126654A1 Novel compound colletoic acid
11/30/2006WO2006126637A1 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
11/30/2006WO2006126625A1 Pharmaceutical comprising pyrazolone derivative
11/30/2006WO2006126581A1 Combination drug
11/30/2006WO2006126529A1 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
11/30/2006WO2006126514A1 Arylacetate derivative having isoxazole skeleton
11/30/2006WO2006126505A1 Stat function inhibitor and application thereof
11/30/2006WO2005080384A9 Benzimidazole derivative and use as aii receptor antagonist
11/30/2006US20060270839 Crystallization of IGF-1
11/30/2006US20060270740 Prostaglandin derivatives
11/30/2006US20060270738 Novel derivatives of 3,3-diphenylpropylamines
11/30/2006US20060270719 2-[(Cyclopropylmethoxy-benzenesulfonyl)-(4-[1,2,3]triazol-2-yl-benzyl)-amino]-N-hydroxy-acetamide; selective inhibitors of matrix-degrading metalloproteinases, especially MT1-MMP, MMP-2 and MMP-9; Osteoporosis; Antitumor, antiproliferative agents
11/30/2006US20060270718 e.g. N-(4-{1-Hydroxy-1-[1-(2-methoxyethyl)-1H-pyrrol-2-yl]-ethyl}-phenyl)-N-methyl-benzenesulfonamide; liver X receptor (LXR) agonist; antidiabetic, antiproliferative agent; lipid, metabolic disorders, obesity, diabetes, hypercholesterolemia, atherosclerosis, hyperlipoproteinemia
11/30/2006US20060270717 Therapeutic combination
11/30/2006US20060270699 Stabilization of hypoxia inducible factor (HIF) alpha
11/30/2006US20060270693 Ether derivative
11/30/2006US20060270691 Purine derivatives as purinergic receptor antagonists
11/30/2006US20060270687 Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states
11/30/2006US20060270681 Pyridazine derivatives
11/30/2006US20060270679 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
11/30/2006US20060270674 Pharmaceutical composition promoting defecation
11/30/2006US20060270665 Combination comprising an agent decreasing VEGF activity and an agent decreasing EGF activity
11/30/2006US20060270660 Processes for preparing substituted pyrimidines
11/30/2006US20060270624 Gapped 2' modified oligonucleotides
11/30/2006US20060270615 Compositions suitable for the treatment of damage caused by ischemia/reper-fusion or oxidative stress
11/30/2006US20060270607 Pharmaceutical combinations
11/30/2006US20060269627 Isolation of a Dual Cox-2 and 5-Lipoxygenase Inhibitor from Acacia
11/30/2006US20060269625 Methods of inhibiting proliferation of cells
11/30/2006US20060269600 Enhancing bioavailability of oral immediate release tablets for low solubility medicants; respiratory inflammatory disorders
11/30/2006US20060269555 Tumor necrosis factor (TNF)-related apoptosis-inducing ligands; anticarcinogenic and antiproliferative agents; graft versus host disease, AIDS, neurodegenerative disorders
11/30/2006US20060269539 Genetic engineering; Alzheimer's agents; anticancer agents
11/30/2006US20060269524 Composition for nkt cell activation